Omalizumab  (Synonyms: Olizumab; rhuMab-E25)

Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE) with a K_D of 0.393 nM. Omalizumab binds to the human FcγRIIb receptors with a K_D of 6.37 uM. Omalizumab has the potential for persistent allergic asthma research^[1][2].

Omalizumab (0.1, 0.5, 1.0, 2.0 μg/mL) has a direct effect on the B cells and can reduce the number of membrane IgE+ cells present in IL-4 plus anti-CD40 treated B cell cultures. Omalizumab alone has no effect on the viable cell number^[3].
Omalizumab (1 μg/mL; 3, 7 days) reduces IL-6 secretion in human B cells. Omalizumab does not induce apoptosis in human B cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Omalizumab (10 mg/kg/day; ip; on day 8 to 42) increases IgE levels in human PBMC-engrafted severe combined immunodeficiency (huSCID) mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

149 (kDa)

242138-07-4

Solid

White to light yellow

[Olizumab]

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Peipei Liu, et al. An Omalizumab Biobetter Antibody With Improved Stability and Efficacy for the Treatment of Allergic Diseases. Front Immunol. 2020 Nov 27;11:596908.  [Content Brief]

  [2]. Seung Y Chu, et al. Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody. J Allergy Clin Immunol. 2012 Apr;129(4):1102-15.  [Content Brief]

  [3]. Marcia A Chan, et al. Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells. Clin Transl Allergy. 2013 Sep 2;3(1):29.  [Content Brief]